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Introduction
Intravitreal anti-vascular endothelial growth factor (VEGF) injections are used with increasing frequency in ophthalmic practice. Numerous large-scale, prospective, randomized, controlled studies have established their efficacy in the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusions (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Three commonly used intravitreal VEGF inhibitors are aflibercept (Eylea®; Regeneron Pharmaceuticals), bevacizumab (Avastin®; Genentech), and ranibizumab (Lucentis®; Genentech), but only aflibercept and ranibizumab have been approved by the Food and Drug Administration for these indications.
Aflibercept, initially named VEGF Trap-eye, is the most recent anti-VEGF agent and is a recombinant fusion protein consisting of human VEGF receptor extracellular domains from receptors 1 and 2 (VEGFR1 and VEGFR2) fused to the Fc domain of human immunoglobulin G (11) .
Pain evaluation during aflibercept injections 64 or inferotemporal), position during injection (sitting or supine), number of previous intravitreal anti-VEGF injections in the study eye, presence of diabetes mellitus or hypertension, and lens status (phakic or pseudophakic).
All injections were done by the same experienced retina specialist (S.D.). Preparation and administration of intravitreal aflibercept injection was performed as recommended in the previously reported guidelines under sterile conditions (15) . The periocular skin, eyelid margins, and eyelashes were cleaned with 10% povidone iodine and 5% povidone iodine was instilled in the conjunctival cul de sac 3 minutes before the injection. A lid speculum was inserted and the injection was performed in the inferotemporal or superotemporal quadrant. Prior to intravitreal aflibercept injection, patients received 2 sets of 0.5% proparacaine (Alcaine, Alcon-Couvreur) topical anesthetic drops. Aflibercept was injected into the vitreous cavity via a 27-G needle inserted through the pars plana 3.5 mm from the limbus in pseudophakic patients and 4.0 mm in phakic patients.
Pain was measured by subjective grading on a VAS, which is a common tool for assessing pain, and has been successfully used in ophthalmologic studies evaluating pain associated with intravitreal injections (16) (17) (18) (19) (20) (21) . The patients received an explanation of the VAS before the injection, and immediately reported the degree of pain they felt during the injection. The VAS included a horizontal line measuring exactly 100 mm and each patient was asked to mark a vertical line crossing the horizontal line according to his or her subjective pain assessment during the injection, ranging from no pain (0) to maximal pain (100). All VAS measurements were done by the same ophthalmologist (S.D.) after explaining this method to the patients.
Statistical analysis was performed with the SPSS software package (Statistical Package for Social Sciences, version 17.0, SPSS Inc.). Quantitative variables were expressed as mean ± standard deviation or median (minimum-maximum), and categorical variables as number and percentage. The normality of quantitative variables was analyzed by Kolmogorov-Smirnov test. Group comparison of VAS pain scores of 2 independent variables was performed with the Mann-Whitney U test, and group comparisons of 3 or more variables with Kruskal-Wallis test. Correlation of VAS pain scores and age or number of previous intravitreal anti-VEGF injections in the study eye was analyzed with Spearman correlation test. Risk factors having a p value less than 0.25 were analyzed for regression coefficient and 95% confidence intervals by multivariable logistic regression analysis with logarithmic transformation to evaluate effect of variables on VAS pain scores. A p value less than 0.05 was considered statistically significant.
Results
A total of 119 patients (63 male, 56 female) with a mean age of 66.4 ± 6.5 years participated in the study. There were no adverse events other than mild subconjunctival hemorrhage reported during or immediately after the intravitreal aflibercept injection. Baseline clinical and demographic characteristics of the patients are summarized in Table I .
Pain scores on the VAS ranged from 9 to 70, with a median of 18. There was no statistically significant correlation between VAS pain scores and variables investigated in the study (Tab. II). No correlation was found with pain scores and patient age (p = 0.339). No statistically significant difference in pain scores was demonstrated for sex (p = 0.737), presence of diabetes (p = 0.272), presence of hypertension (p = 0.506), lens status (p = 0.762), or position during injection (p = 0.096). In addition, there was no difference in pain scores between eyes injected for the first time and eyes that were previously injected (p = 0.408). There was also no significant difference in the pain scores between any of the indications for the injection (p = 0.102). Analysis of pain scores in each location revealed no statistically significant difference between superotemporal and inferotemporal injections (p = 0.842).
There were, however, some small differences in VAS pain scores in terms of parameters evaluated. For example, patients younger than 60 years and between 60 to 70 years of age reported lower VAS pain scores compared to patients older than 70 years. The pain associated with intravitreal aflibercept injection in sitting position was reported to be more painful compared to that of supine position. In terms of the indication for anti-VEGF injection, patients diagnosed with nAMD and macular edema secondary to central retinal vein occlusion (ME-CRVO) reported higher VAS scores compared to the patients diagnosed with DME, but this difference did not reach the statistical significance. The parameters with differences on VAS pain scores were assumed to be potential risk factors associated with higher pain and further evaluated with multivariable logistic regression analysis (Tab. III). The results, however, indicated no statistically significant correlation between any of the parameters (p>0.05 for all).
Discussion
Anti-VEGF injection is an effective treatment for a number of ocular diseases including nAMD, DME, and ME-CRVO (19, 22) . The drug delivery is successfully performed by the direct injection to the posterior segment of the eye, which allows achievement of high intraocular drug levels. Any injection to the eye is already a frightening treatment modality; in addition, the main drawback of anti-VEGF injections is the discomfort and pain felt at the site of injection, which was reported to be not dependent on the drug delivered, and can be reduced, but not eliminated, by topical anesthetics (17) (18) (19) (23) (24) (25) (26) . For example, pain scores on the VAS during intravitreal bevacizumab injection after using 2% lignocaine gel as an anesthetic technique was showed to range from 0 to 84 with a mean of 17.4 ± 17.1 (18). Sanabria et al (25) in their studies comparing the efficacy of 2 different topical anesthetic regimens (5% lidocaine and 0.5% tetracaine) reported that application of topical analgesia resulted in mild pain. Similarly, in our study, topical anesthesia by 0.5% proparacaine was applied before intravitreal injection procedure. Since it is not possible to eliminate the pain associated with injection to the eye, patient comfort and factors associated with the patient's perception of pain are a matter of concern to ensure the patient's compliance with subsequent injections (17, 18, 27) .
Intravitreal aflibercept is a well-tolerated anti-VEGF agent recently approved for the treatment of nAMD, DME, and ME-CRVO (10, 28, 29) . It was reported to be associated with low overall complication rate over 1 million doses between November 2011 and December 2013 (28) . The VIEW study of over 2,000 patients at the 96-week visit documented the frequency of eye pain range from 8.9% to 12.1% (9) . One-year results of the phase 3 GALILEO study with 177 patients reported the incidence of pain as 14.4% of all injections (8) . However, to our knowledge, there are no studies quantifying the pain associated with aflibercept injection and evaluating the factors associated with the patients' comfort. In this series of 119 patients, for the first time in the literature, we quantified pain scores on the VAS after intravitreal aflibercept injection and found VAS scores ranged from 9 to 70, with a median of 18.
Previous studies evaluating the factors affecting the patients' pain during anti-VEGF injection reported confusing results on the dependence of VAS pain scores on female sex and older age (21) . For example, Rifkin and Schaal (19) in their studies comparing Avastin®, Lucentis®, and Avastin®/ Kenalog® injections using visual analog pain score survey indicated less pain associated with female sex compared to that of male patients. The same study showed higher pain scores in patients older than 65 years. Haas et al (30) , comparing the use of a 27-G or 30-G needle in intravitreal injections with the use of topical 0.5% tetracaine, showed the influence of female sex and older age on pain scores. However, a study with 218 patients having an average age of 75.1 ± 10.1 years reported no correlation of pain with the age during or after bevacizumab injection, and revealed no effect of lens status or sex on pain scores on the VAS (18) . A recent study with 112 patients receiving ranibizumab injection indicated no effect of sex, age, or lens status on VAS pain scores (26) . Similarly, in this study, we showed no effect of sex and lens status on the patients' VAS pain scores in relation to aflibercept injection. There was a statistically insignificant increase in the patients' reported pain intensity in patients older than 70 years.
Related with the indications for the injection, similar to the report of Rifkin and Schaal (19) , patients with DME experienced less pain intensity compared to the patients with nAMD and ME-CRVO, probably due to neuropathy opposing the perception of pain. However, there was no statistically significant difference between the patients' perception of pain and the clinical diagnosis requiring anti-VEGF treatment.
There are various reports using either superotemporal (19, 21, 26) or inferotemporal quadrant (20, 25, 30) for the intravitreal injection site and the selection depends on the ophthalmologist's choice. When we compared the injection site (superotemporal vs inferotemporal) we noticed that there was no significant difference in terms of the patient's perception of pain. To our knowledge, there is only one study in the literature comparing the effect of the location of the injection on pain associated with intravitreal bevacizumab injection (18) . Similar to our observation, the study compared the pain scores on the VAS with bevacizumab injection to the superonasal, superotemporal, inferonasal, and inferotemporal quadrants, and proved no statistically significant difference between the patient's perception of pain and different quadrants of the eye (18) .
One of the most important outcomes of our study is the comparison of the effect of position (supine or sitting) during injection on the VAS pain scores. The routine injection position is the supine position, and there is no report in the literature evaluating the pain scores on the VAS in patients with anti-VEGF injection in sitting position. The comparison of data obtained from this series indicated no statistically significant effect of injection in sitting or supine position on the patients' VAS pain scores and there were no adverse events other than mild subconjunctival hemorrhage during the intravitreal aflibercept injection in sitting position. This important outcome will enable injection in sitting position for patients having difficulty staying comfortable in supine position due to, for example, skeletal deformity or respiratory disorder.
The main limitation of the study is the subjective evaluation of pain due to the lack of validated methods for quantifying ophthalmic pain (23, 25) , which does not allow the evaluation of the quality of the pain, such as scratchy, aching, or sharp, and investigation of the effect of other factors, such as personality and emotional state on the perception of pain. The VAS is a sensible method of pain evaluation; however, it is subjective, and quality of the pain is not evaluated by the VAS score. Furthermore, it does not investigate other factors that may bias the results, such as personality and emotional state of patient. The fact that it was not the first injection for many patients could also have influence on the VAS results. The strength of the study is the large number of patients included, which allows for intergroup comparisons and provides a detailed description of several parameters and consistent evaluation. The evaluation of pain right after the injection is important in order to avoid forgetfulness. Additionally, all the injections and the explanation of the questionnaire were done by the same ophthalmologist, which can avoid some bias.
In conclusion, the pain associated with intravitreal aflibercept injection is generally mild and is not associated with demographic or clinical characteristics of the patients.
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